Sunshine Biopharma CEO's 90% consent approves discounted share issuance and Series D warrant repricing

Sunshine Biopharma Inc.

Dr. Steve N. Slilaty, CEO and holder of ~90% of voting power, approved the matters by written consent on October 13, 2026.
Consent covers issuing more than 20% of outstanding common stock at a deemed discount to the Nasdaq Minimum Price, tied to the public offering that closed October 9, 2026.
Also approves exercise-price/share-count adjustments to Series D Warrants in a Share Combination Event (Section 3.7) and voluntary repricing of all outstanding Series D Warrants (Section 3.8).
Consent becomes effective 20 days after the definitive information statement is mailed to stockholders.
Common stock trades as SBFM and the purchase warrants as SBFMW on Nasdaq.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.